DSC2 and prostate carcinoma: Inhibition of DSC2 promotes proliferation, colony formation, migration, and invasion of LNCaP cells and PC-3 cells, and inhibits apoptosis of LNCaP cells and PC-3 cells, which provides a basis for the treatment of prostate cancer (Jiang & Wu, 2020).